申请人:Brooks Harold Burns
公开号:US20100081641A1
公开(公告)日:2010-04-01
The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. Formula I wherein: R
1
is aminomethyl, (C
1
-C
3
alkyl)aminomethyl, di(C
1
-C
2
alkyl)aminomethyl, N-ethyl-N-methyl-aminomethyl, 1-aminoethyl, 1-((C
1
-C
2
alkyl)amino)-ethyl, 3,3,3-trifluoro-propylaminomethyl, ethynyl, 2-hydroxy-ethoxy, 2-hydroxyethylaminomethyl, 2-cyanoethylaminomethyl, mopholin-4-ylmethyl, methoxymethoxymethyl, cyclopropyl, 1-azetidinylmethyl, 1-pyrrolidinylmethyl, or 1,3-dioxolan-2-yl; R
2
is hydrogen or halo; R
3
is hydrogen or halo; provided that at least one of R
2
and R
3
is hydrogen; R
4
is hydrogen, methyl, or halo; and is a single bond that is either present or absent, or pharmaceutically acceptable salt thereof.
本发明提供了一种新型的咪唑啉基氨基嘧啶化合物,通过抑制Plk1,被认为具有治疗癌症的临床用途。公式I如下:其中:R1是氨甲基,(C1-C3烷基)氨甲基,二(C1-C2烷基)氨甲基,N-乙基-N-甲基氨甲基,1-氨基乙基,1-((C1-C2烷基)氨基)-乙基,3,3,3-三氟丙基氨甲基,乙炔基,2-羟基乙氧基,2-羟乙基氨甲基,2-氰基乙基氨甲基,吗啉-4-基甲基,甲氧甲氧基甲基,环丙基,1-氮杂环丙基甲基,1-吡咯烷基甲基或1,3-二氧杂环戊烷-2-基;R2是氢或卤素;R3是氢或卤素;但是R2和R3中至少有一个是氢;R4是氢、甲基或卤素;且是存在或不存在的单键,或其药学上可接受的盐。